Donor Heart Transplants After Circulatory Death Show Matching Survival Rates, While a Separate Study Finds Exercise Beat a Weight-Loss Drug at Reversing Arterial Plaque

More Donor Hearts, Same Survival Odds

Donation after circulatory death, known as DCD, has quietly become one of the biggest shifts in U.S. heart transplantation since the first American case in December 2019. New registry data confirms it's working without a hidden survival penalty.

A study led by Masaki Tsukashita, MD, PhD, of Allegheny General Hospital in Pittsburgh, published in the Annals of Thoracic Surgery, pulled records on 19,432 adult heart transplants from the United Network for Organ Sharing database between December 2019 and December 2025. DCD hearts made up 13.3% of that total.

The numbers were close. Thirty-day mortality was 2.8% for DCD hearts versus 2.7% for hearts from brain-dead donors, a difference with no statistical significance. Five-year survival came in at 77.3% versus 78.3%, again not statistically different, according to MedPage Today's reporting on the study.

DCD hearts did carry real tradeoffs. Recipients had higher rates of severe primary graft dysfunction, 10.3% versus 5.3%, and needed hemodialysis more often, 20.4% versus 16.3%. Both differences were statistically significant. Tsukashita's team wrote that despite the higher dysfunction rate, the findings "provide reassurance and support continued expansion of DCD heart utilization in the United States."

A separate study, appearing in the September 2026 special focus issue of the Journal of Cardiac Failure and distributed via PR Newswire, backed that conclusion from a different angle. Researchers tracked 1,489 adult DCD heart recipients and found no significant differences in one-year graft failure, mortality, need for renal replacement therapy, or hospital length of stay between the early adoption years of 2019-2021 and the broader expansion period of 2022-2024. That issue was guest edited by Ersilia M. DeFilippis, MD, Randall C. Starling, MD, MPH, and Kiran Khush, MD, MAS, and also included papers proposing reforms to how transplant urgency is measured and how immunosuppression could be personalized beyond the standard drug tacrolimus.

The expansion matters because brain death was long the gatekeeper for heart donation. Someone could sign an organ donor card and still die in a way that never qualified, cutting off their heart from ever being used. DCD opened a second path.

That path comes with a real ethical objection, and it deserves to be stated plainly rather than waved off. DCD procurement typically involves restarting a heart outside the body after circulatory death has been declared, while blood flow to the donor's brain is blocked to prevent any recovery of brain function. Critics argue this appears to violate the "dead donor rule," the medical and legal principle that organ retrieval cannot itself cause death and that donors must already be dead before procurement begins. That concern is not fringe. It is the reason DCD heart procurement moved slowly in its early years even as kidney and liver programs adopted it faster.

Researchers are trying to sidestep the controversy with new techniques like "rapid recovery with extended ultraoxygenated preservation," or REUP, which recovers DCD hearts without restarting them in the donor's body at all. Tsukashita's team noted that as procurement methods keep evolving, "additional shifts in DCD utilization patterns and outcomes may emerge."

A Different Study: Exercise Beat a Drug at Shrinking Plaque

A separate line of research, described by Dr. Nicholas Norwitz in a September 15, 2026 Epoch Times newsletter piece, points to a much cheaper intervention producing results that a medication didn't.

According to Norwitz, a trial comparing a year of exercise against a popular weight-loss drug found that exercise lowered inflammation and shrank arterial plaque on imaging, while the drug did not produce the same effect. Norwitz did not name the specific drug or the trial's publication in his piece, so that claim should be read as his account of the data rather than an independently verified clinical trial readout.

Norwitz ties the plaque reduction to a process called clonal hematopoiesis, where a mutated line of blood-forming cells in bone marrow gains a survival edge, crowds out healthy cell lineages, and migrates into artery walls to drive inflammation and plaque buildup. He cites a combined analysis of the UK Biobank and the All of Us Research Program covering more than 90,000 people, which found that more moderate-to-vigorous physical activity, measured with wearable monitors rather than self-reported logs, tracked with less clonal hematopoiesis in both men and women.

Norwitz raises a key counterargument himself. People who exercise more tend to be leaner and generally healthier already, so the association could just reflect who exercises rather than what exercise does. He reports the link held even after researchers adjusted for body weight, which narrows that explanation but doesn't fully settle causation on its own, since adjustment for one confounder doesn't rule out others.

Neither of these stories is a cure-all. DCD expansion still leaves transplant candidates facing a national organ shortage, and clonal hematopoiesis research is still working out exactly how much of it exercise can reverse versus merely slow. Both studies test the same basic question: does the intervention hold up over time, in large numbers of real patients, without the outcomes quietly getting worse. So far, on the data reported, DCD hearts are passing that test. Whether the exercise-versus-drug findings replicate in a larger, independently published trial is the next thing worth watching.